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Formal training to prepare physicians for careers as
investigators in Brazil is still incipient (1). However, the
learning environment is changing dramatically. The compe-
titive arena is transforming the traditional learning environ-
ment into a collaborative and flexible learning environment
(2). Clinical researchers and practitioners ideally share a goal
of increasing the interactions between research and routine
practice in an evidence-based medicine (EBM) environment.
EBM frameworks promote clinically relevant research and
consequently shape the scientific nature of the trainee’s pro-
fessional development. Early experience in clinical research
represents a powerful opportunity to train medical students
to recognize the importance of training with new technologies.
Those students are likely to adopt and maintain this approach
as they progress through further professional achievements.
The Academic Health Centers (AHCs) define a mission
that engages education, research and advances in clinical
care. Determining the value of its integration requires con-
sideration of all stakeholders involved in the support for,
investment in and profit from a center. The strategic planning
for each institution can be implemented if leadership under-
stands the importance of its internal stakeholders’ contribu-
tions and how to create value from integration. Institutions
should identify strategies to successfully create value from a
collaborative engagement that cannot be achieved if the three
elements operate alone. The concept of integration should be
improved to become one of the key elements of institutional
culture. Groups and departments that enhance integration of
the three elements of AHCs should be recognized and
rewarded to strengthen their integrative culture.
The workshop was organized to bring together leading
experts in the field to comprehensively analyze the current
state and future developments of the research, education and
healthcare environment in the Hospital das Clínicas da
Faculdade de Medicina da Universidade de São Paulo, Brazil
(HCFMUSP). The workshop took place on September 14th,
2017, in São Paulo, Brazil, and included more than 30
members of the Hospital das Clínicas and three international
representatives from Charité University, Stanford University,
and the University of Coimbra. Each international represen-
tative provided a presentation with his/her experience. After
the presentations, the working groups included invited mem-
bers for discussions.
The discussing group of clinical research topics addressed
critical points in integrating the human research program to
education and healthcare. The information raised was orga-
nized and considered useful in providing insights and recom-
mendations. The content of this manuscript was prepared by
the members of the clinical research committees. The manu-
script attempts to summarize the most salient points from
members’ reports and to provide the framework for a coor-
dinated effort to address each of the discussed topics.
The HCFMUSP is a hospital complex located in the city of
São Paulo, Brazil. The HCFMUSP is an autarchy of the State
of São Paulo and is associated with the Faculty of Medicine
of the University of São Paulo (FMUSP). The mission of the
HCFMUSP is to provide medical education and research in
order to deliver excellency in health services provided to the
community.
The healthcare at the HCFMUSP is concentrated on disease
prevention, medical-hospital care, tertiary care, and rehabilita-
tion. Academically, the HCFMUSP provides undergraduate
courses and broad and specific postgraduate courses. Research
in most of the branches of the health sciences is conducted
through its 62 medical research laboratories and clinical research
centers in specialized institutions (3,4).DOI: 10.6061/clinics/2017/e515s
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COMMENTS
Since its inauguration on April 19, 1944, the HCFMUSP
has been considered one of the most important Brazilian
AHCs for the dissemination of technical and scientific know-
ledge (4). The HCFMUSP has approximately 380,000 m2,
with 42,000 beds and 415,000 professionals in a variety of
fields and specialties in different facilities as follows:
 Central Institute or Instituto Central (ICHC)
 Ambulatory Building or Prédio dos Ambulatórios (PAMB)
 Orthopedic and Trauma Institute or Instituto de Ortopedia
e Traumatologia (IOT)
 Psychiatry Institute or Instituto de Psiquiatria (IPq)
 Child Institute or Instituto da Crianc¸a (ICr)
 Cancer Institute of the State of São Paulo or Instituto do
Câncer do Estado de São Paulo (ICESP)
 Heart Institute or Instituto do Corac¸ão (InCor)
 Radiology Institute or Instituto de Radiologia (InRad)
 Rehabilitation and Physical Medicine Institute or Instituto
de Medicina Fı´sica e Reabilitac¸ão (IMREA)
 Auxiliary Hospital of Suzano or Hospital Auxiliar de Suzano
(HAS)
 Auxiliary hospital of Cotoxo or Hospital Auxiliar de Cotoxó
(HAC)
 Units
 Administration Building or Prédio da Administrac¸ão
 AIDS House or Casa da AIDS
 Rebouc¸as Convention Center or Centro de Convenc¸ões
Rebouc¸as (CCR)
 Laboratories
 Medical Research Laboratories or Laboratório de Investi-
gac¸ões Médicas (LIM) 1 to 62.
The importance of an international network
With the emerging global burden of chronic diseases,
infections and inequalities, it is crucial for AHCs to have a
global reputation. Networking with international collabora-
tors enriches discussions for potential solutions because of
the integration of multinational perspectives. AHCs have
emerged across the globe with a variety of institutional con-
figurations and strategic approaches. However, universal
elements are present among all of them. The three invited
institutions shared experiences on improving research capa-
city in line with healthcare and strategies to successfully
advance the medical education. The University of Coimbra
brought experiences accumulated since its foundation in
1290, whereas the University of São Paulo was founded in
1935. The working group and others (5,6) reported a growing
trend of academic partnerships between U.S., Canadian, and
European health science institutions and AHCs from low-
and middle-income countries. Research has been identified
as one of the main reasons of this global movement and will
gain increasing importance. For example, the change in para-
digm in 2003 by the Human Genome Project unfolded new
strategies in precision clinical research. The use of patient
molecular data to enrich participant selection for a given trial
or a personalized treatment is becoming routine (7), although
more slowly than initially forecasted. This new ‘‘taxonomy’’,
however, strongly limits accrual and, as a consequence,
screening success has decreased drastically (8). To achieve
sample targets, studies depend on multicenter and multi-
national collaborations to access a large, genetically diverse
and pool of potential research participants (9,10). Precision
clinical research is often complex and involves multiple
stakeholders including physicians, the bioscience industry,
high-tech laboratories, patients, and AHCs in several coun-
tries. These partnerships often encounter challenges such
as resource disparities, which may affect expectations (5).
The present workshop activities yielded an interactive pro-
cess of action, assessment, and reflection to consider that
project objectives and values should be aligned in order
to ensure mutually beneficial objectives. In global diseases,
multinational collaborations would produce powerful know-
ledge for humanity, as the involved AHCs worldwide
would transfer or exchange technology and develop an
updated research capacity for questions of the contempor-
ary era.
Clinical research environment
AHCs need to continuously update methodologies to sup-
port good research practices. Clinical research is conducted
by principal investigators and/or departments in many Insti-
tutes of the HCFMUSP. The working group raised con-
siderations about the lack of uniformity in the procedures
and processes for research execution in Institutes housing
several departments. One advantage of a decentralized model
is to maintain research projects under the supervision of
each department and/or the principal investigator, which
often enhances faculty satisfaction based on greater sense
of autonomy. Although this model appears valid, decen-
tralized operations may result in duplicated infrastructure
which underutilizes resources and requires distinct admin-
istrative approaches to adapt to the culture of different
departments. This model is also not scalable if institutions
invest in clinical investigators and the volume of clinical
research grows, especially if it grows quickly. Compliance
oversight, often not a priority of individual investigators, is
more effective with a specific internal policy (11).
Investigators from the HCFMUSP wish to increase parti-
cipation in rapidly evolving multinational research projects.
In the last few years, the importance of multinational clinical
research participation gained increasing attention result-
ing in the creation of a Board for Clinical Trials Facilitation
to deliver solutions to the Office of Clinical Trials of the
HCFMUSP in order to improve clinical research capacity
(12). In line with the HCFMUSP organizational movement,
that Board raised a critical point: the centralized model for
research activities should be applied within each institute. In
recent years, the institutional office of clinical trials (OCT)
has emerged in AHCs to consolidate administrative activities
related to clinical research (13). This organizational shift has
typically increased research capabilities and management
and has helped to achieve sustainability and growth. Similar
to the University of Coimbra and the Stanford University
Cancer Institute, the Cancer Institute, Heart Institute and
Central Institute of the HCFMUSP have already established
OCTs (14). Many interdependent functions are intersected
with the research entity, which require an administrative
structure for communications and interactions with distinct
internal and external players. The emergence of OCTs is a
demand of a growing requirement of stakeholders to be
linked formally and harmonized in an efficient way (13).
OCTs require institutional investment to support operational
activities. Thus, the goals and results of OCT implementation
should be clear to the leaders.
Clinical research activities are moving toward a high level
of complexity in which investigators need support to accomplish
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all tasks. Some key activities of OCTs should include the
following.
Support for clinical trials agreements (CTAs). Research
projects often include sponsors or donations that will require
institutional mediation or oversight. The formal legal instru-
ment is a contract agreement between the parties. CTAs are
separated from confidentiality agreements or investigators’
agreements and are not regulated by regulatory agencies
such as the Food and Drug Administration. CTAs are critical
in dividing and protecting the responsibilities of each party,
specifically the risks, financial support, rights and obliga-
tions. Usually, negotiation would need final approval of the
legal department. Thus, the negotiators should be aware
of basic legal requirements for clinical trial conduction. The
costs of the institution, health insurance, clinical research
insurance, percentage of overhead, hidden costs and other
aspects of research budgeting should be considered and
calculated as to avoid loses. Publication policy, intellectual
and industrial property, data control and any other aspects
of information should be stated in CTAs. A harmonized
template containing all of the standard requirements of the
institution and investigators should be adopted by OCTs.
Clinical operations. Clinical trials require operational
management to coordinate the project at any phase. The
clinical trial coordinator at a local/institutional level will
organize the logistic supply, treatment schedule, accrual
activities and patient agendas. Protocol-related procedures
are better controlled by a dedicated administrative trial
coordinator from an OCT. Information technology and clini-
cal trial management systems can be organized by the OCTs
to provide best tools for each trial. One quality-related opera-
tion would be to conduct clinical trials in accordance with
Good Clinical Practice (GCP) and International Conference
of Harmonization (ICH) guidelines.
Regulatory affairs. All clinical research is monitored by
the government, as it is critical for safety reasons. Institutions
would need a dedicated staff to liaise with regulatory bodies
to avoid delays in receiving approvals. Regulatory liaison
specialists can facilitate submissions to an institutional review
board (IRB), an ethics committee (EC), and any other regula-
tory or sanitary authority. These specialists can organize the
protocols’ dossier and anticipate potential queries and pend-
ing documents. This group is critical to support investigators
in maintaining good communication with regulatory bodies,
which is a major aspect stated in the GCP guidelines.
Training. GCP guidelines are a major standard for all cli-
nical research. The ability to offer GCP training to all invol-
ved staff is desirable in order to harmonize data quality
while strengthening the staff’s ethical standards. Specific
protocol-related training may also be organized by OCTs.
Patient recruitment and retention. In the past decades,
it has been difficult to achieve sample targets in clinical trials,
while fewer patients are finishing studies (15). OCTs can
provide support in maintaining an organized patient data-
base to enhance accrual efficiency and help investigators
with patient retention strategies.
Quality oversight. Quality assurance of clinical research
should be implemented to all research activities, particularly
for safety reasons and for the quality of data. An organi-
zed OCT could implement or improve quality control by
providing or promoting specific training and establishing
staff minimum requirements for clinical research conduct.
Each study may be monitored, and deviations or any other
issues found in audit visits can be followed up. OCTs should
organize a continuous process of quality improvements by
revising communications and processes involving investiga-
tors and support staff.
Encouraging and motivating physician-
investigators
An important barrier that was noted during discussions
in the workshop was the lack of time and motivation for
research activities. Early career clinical investigators without
proper training, dedicated research time or mentorship may
experience substantial challenges and early failure in the
conduct of clinical research, leading to a sense of emotional
exhaustion. It is estimated that 16% of early career investi-
gators experience burnout in this scenario. Moreover, a
higher rate burnout (approximately one third) is found
among physician-investigators who are over 35 years of age
(16). Dedicated time for investigators to conduct research was
a key consideration of the working group. Each institution
would need to organize demands to allocate research activities
while routine care is maintained (and improved). As per GCP
guidelines, the investigator should have sufficient time to
properly conduct and complete the trial within the agreed trial
period (GCP 4.2.2) (17). It is also valuable for institutions
to provide extra support to minimize personal hazards
associated with professional burnout in all domains of the
academic mission.
OCTs also act as supportive units for physicians to
dedicate more time to clinical investigations. The academic
physician-investigator faces several pitfalls. Obtaining fund-
ing to support research, more emphasis placed on clinical
practice to generate funds, and increasing paperwork needed
to comply with regulatory requirements are the tip of the
iceberg (15,18). These facts may jeopardize the retention of
young faculty members. OCTs may help in providing spe-
cialized support in navigating and coordinating clinical
research ranging from the administration of contracts and
budgets, subject recruitment and retention strategies, and
data collection and quality to the care of research subjects
(19,20).
Compliance and integrity of AHCs
Recently, compliance activities have been critically impor-
tant to ensure adherence to local, state and federal regulations
pertaining to research, healthcare and education activities. Ties
with pharmaceutical and device industries, among others, are
common in medical research and practice, which may result in
benefits through research collaborations that improve indivi-
dual and public health. On the other hand, such relationships
may create individual potential conflicts of interest. Such
conflicts may threaten the integrity of scientific investiga-
tions, medical education and the quality of patient care (21).
Research deviations, financial issues or any other miscon-
duct behavior or process should be monitored by an orga-
nized commission that should work closely with the office
of the general counsel and the office of internal auditing.
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Policies generally emphasize prevention and management
rather than punishment. In AHCs, students may not under-
stand the risks posed by conflicts of interests; thus, more
education regarding compliance and integrity should be
considered.
Clinical research governance and the use of
technology
The working group promptly indicated that the HCFMUSP
is a complex organization. Multiple institutions, units and
laboratories were built up on different occasions according
to public healthcare demands of contemporary diseases.
Leadership units are immediately facing internal structural
challenges derived from faculty practices and distinct schools
and cultures. Each institute poses particular governance
characteristics. The working group has raised the importance
of establishing strategic intersections in the centralized gov-
ernance of the HCFMUSP, while maintaining the particula-
rities of each institution.
The working group agreed that technology for healthcare
and research purposes is constantly improving to enhance
operational efficiencies. An integrated information system
is necessary to link electronic medical records (EMRs) to
decision support systems, supply control, work flows, and
revenue cycle management programs to appropriately asses-
sthe cost effectiveness of treatment, etc. An integrated system
would necessitate the implementation of a management
system covering the complete spectrum of care, from pri-
mary care units to specialized quaternary institutions. This
system however, would need a policy for data control.
Integrating any data from a myriad of distinct sources is a
key solution to refine patient particularities but would create
a tremendous volume of information under which conven-
tional processing methods may simply collapse. Big data
covers data retrieval, handling, and analyses of massive data
(22). Integration of all data produced and managed by the
HCFMUSP needs a careful review and analysis from the
central governance perspective.
Comprehensive cancer center
The working group considered the valuable, potential
application of the Comprehensive Cancer Center model to
the Cancer Institute of the HCFMUSP. The US National
Cancer Institute (NCI) has characterized cancer centers based
on their size and complexity. The largest type is the Com-
prehensive Cancer Center (CCC), which is devoted to cli-
nical, basic and epidemiological cancer research to advance
diagnostic, treatment and preventive methods in most or all
cancers (23). CCCs can be organized as centers of excellence
that are not limited to research but to patients looking for
state-of-art treatment and access to clinical trials. The research
is multidisciplinary, and complex studies are made possible
by the collaboration and supportive technology platforms
in the center structure. This would need a high capacity
of articulating coworkers with common objectives. Thus,
the organizational structure aims to bridge clinical pro-
grammers and supporting disciplines in a matrix to better
achieve their interactions (23). The CCCs and cancer centers
may be organized to collaborate in answering particular
and urgent questions. In Brazil, the Ministry of Health and
Ministry of Science, Technology and Innovation launched
the National Clinical Trials Network (NCTN) in 2005,
and a specific group was dedicated to oncology studies.
This group aims to collaborate on projects that would not
be feasible at single sites. The main objective of the NCTN
is to promote health innovation facilitated by an organized
infrastructure that eventually improves the national research
capacity (24,25). The organization and modus operandi are,
Table 1 - Recommendations for clinical research improvements and integration into medical education and healthcare in AHCs.
Incentive for networking  Develop strategies to improve international collaboration between AHCs to answer/overcome
global challenges and exchange experiences
Promote research integrity  Adopt conflict of interest policies and integrity policies for AHCs and their institutions
 Implement and strengthen disclosure policies
Research culture  Implement or improve a comprehensive strategy to motivate and engage physician-investigators
 Develop a research culture together with the commitment to research quality, which are essential
Use of technology  Address information technology strains that are preventing data sharing and access among different providers
 Carefully consider the complex integration of data produced by the multi-institutional HCFMUSP from
the central governance perspective
Office of Clinical
Trials (OCT)
 Consider developing OCTs to organize research activities under standardized policy; OCTs should consolidate
critical research activities
3 This would require institutional investment to support routine operational needs as follow
 OCTs would support the management of studies and regulatory submissions to the ethics committees and
any other regulatory instances
3 OCTs would oversee compliance enforcement, conduct regulatory and safety monitoring on an ad hoc basis
and related to specific trials
3 OCTs may offer support in using technology such as clinical trial management systems, electronic clinical report
forms (eCRFs) and other tools related to clinical research databases, as well as data retrieval and analysis
3 OCTs would support investigators with fiscal operations, increasing transparency for compliance purposes
3 Trained staff to support clinical operations should be efficiently organized in terms of costs
3 OCTs may offer support to small research groups or studies focusing on rare or neglected diseases
Governance  Establish an organizational plan updating the main priorities to deal with current and future research and
healthcare challenges from the city, state and country perspectives
 Prioritize clearer values from collaboration among three elements: education, research, and healthcare
 Implement actions that reap the benefits from integration that otherwise would not be possible if operating alone
 Support new projects that promote the adequate use of resources such as equipment sharing and merging of
replicated, specialized medical teams in corporate consolidated staff
 Consider the application and adaptation of the comprehensive cancer center model to specialized institute such as
the Cancer Institute of HCFMUSP
 Consider the identity and culture of institutions as major aspects in the integration power of multi-institutional
AHCs such as HCFMUSP
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however, challenging and depend on the government ini-
tiatives. In 2009, the Cancer Institute of the HCFMUSP
coordinated a NCTN multicenter study sponsored by the
Brazilian National Council for Scientific and Technological
Development (CNPq) (26). The project was implemented and
successfully conducted (trial number NCT01370239). Never-
theless, the initiatives are still few. Recently, the reorganization
of the NCTN was a topic of discussion in the meeting pro-
moted by the Brazilian Ministry of Health to recover and to
add greater strategic importance to the network (27).
The organization systems of CCCs may be applicable to
Brazilian cancer centers. However, some critical points should
be addressed. The internal organization of the cancer center
should be multidisciplinary and often requires establishment
or improvement of a collaborative culture. The OCTs may
help in organizing CCCs, as this model gathers several
departments and disciplines in response to common research
questions. The CCCs and cancer centers are organized in a
network for referral. For instance, many patients are referred
to rehabilitation services of the University of Texas MD
Anderson because is the only cancer center to have this
facility (28). In Brazil, the policy for patient referral needs
further improvement, as the demands for the public health
system need to be better equalized.
Taken together, the group suggested recommendations
(Table 1) to improve clinical research activities and strategies
to better synchronize medical research with education and
healthcare.
The role of clinical research in AHCs is expanding, as
medical services face challenges imposed by new paradigms.
Collaboration with different departments/institutes/units
to integrate clinical trials with healthcare and education is
always challenging, and all efforts should be continuously
implemented to achieve the best possible level of organiza-
tion. Here, we recommend some actions and suggestions for
consideration. These suggestions should be adapted for each
institution, as we understand that particular characteristics
should be respected. It is noteworthy that the creativity of the
investigator and inherent needs for independence and
autonomy are important to preserve with the centralization
of resources. Overall, the workshop was a great opportunity
to exchange knowledge and experience to move forward in a
complex scenario of clinical research of the modern era.
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